The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 20, 2022

Filed:

Jul. 26, 2018
Applicants:

Bioinvent International Ab, Lund, SE;

Cancer Research Technology Limited, London, GB;

Inventors:

Björn Frendéus, Lund, SE;

Linda Mårtensson, Bjarred, SE;

Monika Semmrich, Malmo, SE;

Ingrid Teige, Lund, SE;

Stephen Beers, Southampton, GB;

Aymen Al-Shamkhani, Southampton, GB;

Juliet Gray, Southampton, GB;

Martin Glennie, Southampton, GB;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2815 (2013.01); C07K 16/2878 (2013.01); A61K 2039/507 (2013.01); C07K 16/2827 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01);
Abstract

Described is the sequential administration of first a Treg depleting antibody molecule selected from antibody molecules, such as an antibody molecule binding specifically to target belonging to the tumour necrosis factor receptor superfamily (TNFRSF), such as a Treg depleting anti-4-1 BB antibody or a Treg depleting OX-40 antibody, and then an immunostimulatory antibody molecule, such as an immunostimulatory anti-4-1 BB anti-body or an immunostimulatory OX-40 antibody, for use in the treatment of cancer. Described are also novel anti-4-1 BB antibodies and novel OX-40 antibodies that may be used in such sequential administration.


Find Patent Forward Citations

Loading…